186 related articles for article (PubMed ID: 37183462)
21. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
22. Targeting DNA-PK in cancer.
Damia G
Mutat Res; 2020; 821():111692. PubMed ID: 32172133
[TBL] [Abstract][Full Text] [Related]
23. Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.
Genta S; Martorana F; Stathis A; Colombo I
Crit Rev Oncol Hematol; 2021 Dec; 168():103539. PubMed ID: 34800653
[TBL] [Abstract][Full Text] [Related]
24. Targeting DNA damage response in cancer therapy.
Hosoya N; Miyagawa K
Cancer Sci; 2014 Apr; 105(4):370-88. PubMed ID: 24484288
[TBL] [Abstract][Full Text] [Related]
25. DNA Repair.
Borgmann K; Köcher S; Kriegs M; Mansour WY; Parplys AC; Rieckmann T; Rothkamm K
Recent Results Cancer Res; 2016; 198():1-24. PubMed ID: 27318679
[TBL] [Abstract][Full Text] [Related]
26. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
27. DNA repair functions that control sensitivity to topoisomerase-targeting drugs.
Malik M; Nitiss JL
Eukaryot Cell; 2004 Feb; 3(1):82-90. PubMed ID: 14871939
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Targeting of DNA Replication Stress in Cancer.
Gu L; Hickey RJ; Malkas LH
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510250
[TBL] [Abstract][Full Text] [Related]
30. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
31. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Zimmermann M; Murina O; Reijns MAM; Agathanggelou A; Challis R; Tarnauskaitė Ž; Muir M; Fluteau A; Aregger M; McEwan A; Yuan W; Clarke M; Lambros MB; Paneesha S; Moss P; Chandrashekhar M; Angers S; Moffat J; Brunton VG; Hart T; de Bono J; Stankovic T; Jackson AP; Durocher D
Nature; 2018 Jul; 559(7713):285-289. PubMed ID: 29973717
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
33. Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair.
Croglio MP; Haake JM; Ryan CP; Wang VS; Lapier J; Schlarbaum JP; Dayani Y; Artuso E; Prandi C; Koltai H; Agama K; Pommier Y; Chen Y; Tricoli L; LaRocque JR; Albanese C; Yarden RI
Oncotarget; 2016 Mar; 7(12):13984-4001. PubMed ID: 26910887
[TBL] [Abstract][Full Text] [Related]
34. Translesion DNA Synthesis in Cancer: Molecular Mechanisms and Therapeutic Opportunities.
Zafar MK; Eoff RL
Chem Res Toxicol; 2017 Nov; 30(11):1942-1955. PubMed ID: 28841374
[TBL] [Abstract][Full Text] [Related]
35. Targeting the DNA Damage Response in Cancer.
O'Connor MJ
Mol Cell; 2015 Nov; 60(4):547-60. PubMed ID: 26590714
[TBL] [Abstract][Full Text] [Related]
36. DNA damage repair in breast cancer and its therapeutic implications.
Ali R; Rakha EA; Madhusudan S; Bryant HE
Pathology; 2017 Feb; 49(2):156-165. PubMed ID: 28034453
[TBL] [Abstract][Full Text] [Related]
37. PARP1-modulated chromatin remodeling is a new target for cancer treatment.
Sinha S; Molla S; Kundu CN
Med Oncol; 2021 Aug; 38(10):118. PubMed ID: 34432161
[TBL] [Abstract][Full Text] [Related]
38. Targeting the DNA damage response for cancer therapy.
Curtin NJ
Biochem Soc Trans; 2023 Feb; 51(1):207-221. PubMed ID: 36606678
[TBL] [Abstract][Full Text] [Related]
39. DNA damage response and prostate cancer: defects, regulation and therapeutic implications.
Karanika S; Karantanos T; Li L; Corn PG; Thompson TC
Oncogene; 2015 May; 34(22):2815-22. PubMed ID: 25132269
[TBL] [Abstract][Full Text] [Related]
40. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
